NBIX: Summary for Neurocrine Biosciences, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 5:17am EST - Canadian Markets open in 4 hours and 13 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Neurocrine Biosciences Inc. (NBIX)

On Feb 9: 2.37 USD 0.00 (0.00%)

MORE ON NBIX

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Neurocrine Biosciences, Inc. (NasdaqNM:NBIX) Delayed quote data

Last Trade:	2.37 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	2.37
Open:	N/A
Bid:	N/A
Ask:	6.00 x 200
1y Target Est:	3.67

Day's Range:	N/A - N/A
52wk Range:	1.94 - 4.25
Volume:	0
Avg Vol (3m):	188,943
Market Cap:	92.92M
P/E (ttm):	N/A
EPS (ttm):	-1.85
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add NBIX to Portfolio

Download Data

HEADLINES

•	NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of I
	EDGAR Online (Tue 2:17pm)

•	Neurocrine names CEO of Receptos to its board
	AP (Mon, Feb 8)

•	Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
	PRNewswire (Mon, Feb 8)

•	New Star Analyst Rankings for Neurocrine Biosciences, Inc.
	StarMine (Thu, Feb 4)

•	Neurocrine Biosciences Inc. Q4 2009 Earnings Call Transcript
	at Seeking Alpha (Wed, Feb 3)

•	NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Wed, Feb 3)

•	Neurocrine Biosciences Reports Fourth Quarter and Year-End 2009 Results
	PRNewswire (Wed, Feb 3)

•	Q4 2009 Neurocrine Biosciences, Inc. Earnings Release - After Market Close
	CCBN (Wed, Feb 3)

•	Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results
	PRNewswire (Wed, Jan 27)

•	Neurocrine Advances VMAT2 Inhibitor Program
	PRNewswire (Mon, Dec 21)

More Headlines for NBIX...

ANALYST

EPS Est (next year) (Dec-10) :	-0.81
EPS Est (in 2 years) (Dec-11) :	-0.91
Avg Rec (current)*:	2.7
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•